(Q42506718)

1 November 2017

title

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer (English)

1 reference

1 November 2017

Tobias J Grob

1

1 reference

1 November 2017

Uwe Heilenkötter

2

1 reference

1 November 2017

Stefan Geist

3

1 reference

1 November 2017

Peter Paluchowski

4

1 reference

1 November 2017

Christian Wilke

5

1 reference

1 November 2017

Fritz Jaenicke

6

1 reference

1 November 2017

Alexander Quaas

7

1 reference

1 November 2017

Waldemar Wilczak

8

1 reference

1 November 2017

Matthias Choschzick

9

1 reference

1 November 2017

Guido Sauter

10

1 reference

1 November 2017

Annette Lebeau

11

1 reference

1 November 2017

language of work or name

English

0 references

publication date

19 May 2012

1 reference

Breast Cancer Research and Treatment

1 November 2017

published in

1 reference

1 November 2017

volume

134

1 reference

1 November 2017

issue

2

1 reference

1 November 2017

page(s)

561-567

1 reference

Triple-Negative Breast Cancer

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Molecular stratification of triple-negative breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

EGFR expression and gene copy number in triple-negative breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Ras oncogenes: split personalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Diverse somatic mutation patterns and pathway alterations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Tissue microarrays for high-throughput molecular profiling of tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Absence of EGFR mutation in the kinase domain in common human cancers besides non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2092-7

10.1007/S10549-012-2092-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 November 2017

1011880175

0 references

1 reference